PMID- 35702931
OWN - NLM
STAT- MEDLINE
DCOM- 20231115
LR  - 20231115
IS  - 1531-1937 (Electronic)
IS  - 0897-1900 (Linking)
VI  - 36
IP  - 6
DP  - 2023 Dec
TI  - Alogliptin Induced Stomatitis: An Adverse Drug Event Case Report.
PG  - 1516-1518
LID - 10.1177/08971900221108721 [doi]
AB  - Background: Dipeptidyl peptidase (DPP)-4 inhibitors are commonly used agents to 
      treat type 2 diabetes mellitus (T2DM). Although generally well tolerated, 
      stomatitis has been previously reported as an adverse event with sitagliptin and 
      linagliptin. Stomatitis with alogliptin has not been reported in post-marketing 
      data to date. Objective: To report a case of suspected drug-induced stomatitis in 
      a patient who received alogliptin for T2DM which resolved upon discontinuation of 
      the offending agent. Summary: A 60-year-old male with T2DM began treatment with a 
      DPP-4 inhibitor, alogliptin. After 4 doses of alogliptin, the patient reported 
      inflammation and irritation along the lateral borders of his tongue, along with 
      open fissures and oral ulcerations on the dorsal surface of the mucosa. He was 
      subsequently diagnosed with stomatitis. Patient discontinued alogliptin and 
      reported improvement in symptoms within 48 hours. Lesions re-epithelialized 
      within 4 weeks after cessation of alogliptin. The Naranjo Algorithm was used to 
      assess causality. The total score was 7, which when interpreted, implicates 
      alogliptin as a "probable" cause of the reaction. Conclusion: A causality 
      assessment determined alogliptin was a "probable" cause of stomatitis experienced 
      by this patient. This adverse effect has not been reported with alogliptin to the 
      authors' knowledge.
FAU - Terry, Danielle
AU  - Terry D
AD  - Veterans Health Care System of the Ozarks, Fayetteville, AR, USA. RINGGOLD: 19964
FAU - Eads, Andrea V
AU  - Eads AV
AUID- ORCID: 0000-0002-8760-0038
AD  - Veterans Health Care System of the Ozarks, Fayetteville, AR, USA. RINGGOLD: 19964
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20220615
PL  - United States
TA  - J Pharm Pract
JT  - Journal of pharmacy practice
JID - 8900945
RN  - JHC049LO86 (alogliptin)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 56HH86ZVCT (Uracil)
SB  - IM
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - *Stomatitis/chemically induced
MH  - *Uracil/adverse effects
OTO - NOTNLM
OT  - adverse drug reaction
OT  - alogliptin
OT  - diabetes mellitus
OT  - oral ulceration
OT  - stomatitis
COIS- Declaration of Conflicting InterestsThe author(s) declared the following 
      potential conflicts of interest with respect to the research, authorship, and/or 
      publication of this article: Neither author has any conflict of interest to 
      report. This material is the result of work supported with resources at the 
      Veterans Health Care System of the Ozarks. The contents do not represent the 
      views of the U.S. Department of Veterans Affairs or the United States Government.
EDAT- 2022/06/16 06:00
MHDA- 2023/11/08 06:43
CRDT- 2022/06/15 03:35
PHST- 2023/11/08 06:43 [medline]
PHST- 2022/06/16 06:00 [pubmed]
PHST- 2022/06/15 03:35 [entrez]
AID - 10.1177/08971900221108721 [doi]
PST - ppublish
SO  - J Pharm Pract. 2023 Dec;36(6):1516-1518. doi: 10.1177/08971900221108721. Epub 
      2022 Jun 15.